Driven by a passion to find solutions for unmet needs in pulmonary medicine, Erin McGurk founded PneumRx in 2004. That same year, Kara Andersen Reiter, Mark Mathis and Dave Thompson joined Erin. The team started intense market and clinical research with Interventional Pulmonologists all over the world. From that work, the RePneu® Coil, an endobronchial treatment that addresses the key challenges in emphysema management was developed.
The first patients were treated in 2008 and by 2010 the product was CE-Mark labeled. 2011 was the first full year the RePneu Coil treatment was available in Europe. In that same year, the company submitted a protocol to FDA based on the excellent safety and effectiveness data from the studies conducted in Germany and the Netherlands. In 2012, the RePneu Coil was one of two therapies selected by the French Ministry of Health for a new technology project (STIC) to prospectively evaluate the RePneu Coils in a randomized controlled trial with health economic analysis. The French Study completed enrollment 5 months early. In October 2014, the FDA IDE clinical trial completed enrollment, 3 months early. The RePneu Coil treatment is now available in about 20 countries globally.
For 10 years, PneumRx leadership and all of its employees have been devoted to supporting clinicians in improving the standard of care with innovative medical technologies for millions of emphysema sufferers worldwide.